Core Insights - The article highlights the accelerated pace of institutional research on A-share listed companies as they release their 2025 performance forecasts, indicating a proactive approach to investment strategies for the new year [1] Group 1: Institutional Research Trends - Over 700 A-share listed companies have received institutional research since the beginning of the year, with over 20 companies attracting more than 100 institutions each [1] - Key sectors attracting attention include electronics, machinery, and pharmaceuticals, with power equipment and non-ferrous metals also being closely monitored [1] Group 2: New Product Launches - Several companies have announced accelerated timelines for new product mass production, showcasing confidence in growth for the new year [2] - Nepean Mining revealed plans to globally promote its innovative composite liner product in 2026, supported by the gradual production ramp-up of overseas facilities [2] - Huqin Technology's robotics division is set to deliver mass-produced robots in 2026, following significant advancements in R&D and project execution [2] - Jiemai Technology is investing in a production line for critical products, with mass production expected by mid-2026 [2] Group 3: Brain-Computer Interface Developments - Companies like Xiangyu Medical and Aipeng Medical are focusing on brain-computer interface technologies, with Xiangyu Medical planning to launch nearly 100 products by the end of 2026 [3] - The integration of software with rehabilitation equipment is expected to enhance product offerings and market competitiveness [3] Group 4: Industry Expansion and Growth - The demand for AI and computing power is driving growth in sectors like optical communication and liquid cooling, prompting companies to accelerate production capacity [4] - Daikin Heavy Industries reported a tight production schedule for overseas projects, anticipating significant growth in offshore wind energy markets [4] - Zhongji Xuchuang noted a strong order backlog extending into Q4 2026, indicating sustained high demand in the industry [4] Group 5: Storage and Liquid Cooling Innovations - Dike Technology plans to increase its storage chip output target to between 30 million and 50 million units in 2026, aiming to enhance revenue and net profit [5] - Dingtong Technology is expanding its liquid cooling production capabilities to meet rising customer demand [5] - Haitai Ruisheng is building a second overseas delivery base in Southeast Asia, expected to support significant orders from major tech clients [5] Group 6: Mergers and Acquisitions - Companies are increasingly pursuing mergers and acquisitions to enter new markets and drive growth [6] - Yingtang Zhikong plans to acquire Guanglong Integration and Aojian Microelectronics to enter the optical communication sector [6] - Dinglong Co. is acquiring Haofei New Materials to tap into the lithium battery functional materials market, with expected sales growth in 2026 [6] Group 7: Strategic Investments - Tianlu Technology is reallocating funds to projects aimed at enhancing its product offerings in the display industry, with equipment for the TAC film project expected to be operational by mid-2026 [7]

Core Insights - The article highlights the accelerated pace of institutional research on A-share listed companies as they prepare for investment opportunities in 2026, with over 700 companies receiving institutional inquiries since the beginning of the year [2] Group 1: Institutional Research Trends - More than 700 A-share listed companies have been visited by institutional investors for research since the start of 2026, with over 20 companies attracting more than 100 institutions each [2] - Key sectors attracting attention include electronics, machinery, pharmaceuticals, power equipment, and non-ferrous metals [2] Group 2: New Product Launches - Several companies have announced timelines for mass production of new products, indicating a strong growth outlook for 2026 [3] - Nepean Mining revealed plans to globally promote its innovative composite lining board, with production ramping up in 2026 [3] - Huajin Technology's robotics division is set to deliver mass-produced robots in 2026, enhancing flexible manufacturing capabilities [3] - Jiemai Technology is investing in a production line for critical products, expected to achieve scale production by mid-2026 [3] Group 3: Brain-Computer Interface Developments - Companies like Xiangyu Medical are focusing on brain-computer interface technologies, with plans to launch nearly 100 products by the end of 2026 [4] - The integration of software with rehabilitation equipment is expected to enhance product offerings and reduce upgrade cycles [4] Group 4: High-Growth Sector Expansion - The demand for AI and computing power is driving growth in sectors like optical communication and liquid cooling, prompting companies to accelerate production capacity [5] - Daikin Heavy Industries reported a tight production schedule for overseas projects, anticipating significant growth in offshore wind energy markets [5] - Zhongji Xuchuang noted a strong order backlog extending into Q4 2026, indicating sustained demand in the optical module sector [5] Group 5: Storage and Liquid Cooling Innovations - Dike Technology plans to increase its storage chip output target to between 30 million and 50 million units in 2026, aiming for significant revenue growth [6] - Dingtong Technology is expanding its liquid cooling production capacity to meet rising customer demand [6] - Haitan Ruisheng is enhancing its overseas operations, planning to establish a second local delivery base in Southeast Asia by the end of 2026 [6] Group 6: Mergers and Acquisitions for Growth - Companies are increasingly pursuing acquisitions to enter new markets and drive business transformation [7] - Yingtang Zhikong plans to acquire Guanglong Integration and Ao Jian Microelectronics to enter the optical communication sector [7] - Dinglong Co. is acquiring Haofei New Materials to expand into the lithium battery materials market, with expected sales growth in 2026 [7] - Tianlu Technology is reallocating funds to projects aimed at enhancing its product offerings in the display industry [8]

证券之星消息，截至2026年2月4日收盘，美好医疗(301363)报收于32.02元，上涨0.25%，换手率 2.45%，成交量9.13万手，成交额2.89亿元。 2月4日的资金流向数据方面，主力资金净流入197.49万元，占总成交额0.68%，游资资金净流出1103.21 万元，占总成交额3.82%，散户资金净流入905.72万元，占总成交额3.14%。 近5日资金流向一览见下表： 美好医疗2025年三季报显示，前三季度公司主营收入11.94亿元，同比上升3.28%；归母净利润2.08亿 元，同比下降19.25%；扣非净利润2.03亿元，同比下降17.85%；其中2025年第三季度，公司单季度主营 收入4.62亿元，同比上升2.56%；单季度归母净利润9390.02万元，同比上升5.89%；单季度扣非净利润 9270.68万元，同比上升9.56%；负债率11.43%，投资收益490.31万元，财务费用-2739.1万元，毛利率 39.34%。美好医疗（301363）主营业务：医疗器械精密组件及产品的设计开发、制造和销售,为全球医 疗器械企业提供从产品研发到批量交付的全流程一站式服务。 该股最近90天内共有7 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [1] Core Insights - The medical device bidding market is expected to maintain high prosperity in 2025, driven by policy and demand resonance, with a projected market size of CNY 193.76 billion, representing a year-on-year growth of 24% [3][11] - The upward trend for medical device companies is clear for 2026, with multiple policies expected to support the continuous development of medical innovation [4][29] - The report emphasizes the importance of high-end product localization and innovation in driving growth for leading domestic companies [33][41] Summary by Sections Bidding Review - The medical device bidding market in 2025 is projected to reach CNY 193.76 billion, with a year-on-year increase of 24%, second only to the peak in 2022 [3][11] - Monthly bidding trends show sustained high levels, with procurement amounts from July to December ranging from CNY 134 billion to CNY 285 billion [3][11] - Key segments such as medical imaging equipment and radiation therapy devices are expected to see significant growth, with year-on-year increases of 35.37% and 36.34% respectively [3][16] 2026 Outlook - The report anticipates a clear upward turning point for medical device companies in 2026, supported by policies aimed at promoting medical innovation and equipment updates [4][29] - The implementation of large-scale equipment updates and consumer replacement policies is expected to further stimulate market demand [4][29] - The report highlights the potential for domestic companies to benefit from high-end product upgrades and the commercialization of brain-computer interface technologies [4][50] Investment Recommendations - The report suggests focusing on leading domestic companies that are enhancing their high-end and intelligent medical device offerings, such as Mindray, United Imaging, and KaiLi Medical [4][33] - It also recommends monitoring companies involved in brain-computer interfaces and domestic robotics, which are expected to see significant growth in the coming years [4][50]

【中泰医药】脑机动态定期更新 近期部分重要进展： 1、赵继宗院士牵头制定的《植入式脑机接口临床应用路径管理中国专家共识（2026 版）》正式发布，推动 iBCI 临床转化科学、安全、有序发展； 2、民政部印发《关于进一步推进民政科技创新的指导意见》，《意见》要求广泛应用人形机器人、脑机接口、人 工智能等前沿技术，开展失能失智预防和抗衰老、生活照料和康复护理、精神慰藉和社会参与促进、安全风险监 测和紧急救援、老年宜居 仅需3分钟就能迅速打开血脑屏障，与血脑屏障未开放的脑组织相比，药物浓度可以平均提高8倍，并且在治疗后6 小时关闭血脑屏障，疗效和安全性均优于国际相关报道； 7、Ybrain招募三星电子和VUNO前高管，推广基于tDCS和脑电图技术的非口服抗抑郁药、打造AI心理健康生态系 统； 8、韩国数字医疗企业Neofect宣布与韩德联合财团合作，共同推进脑机接口商业化，项目将耗时36个月（2025.9- 2028.8）研发基于脑神经控制的脑卒中患者上肢辅助与康复机器人系统。 【中泰医药】脑机动态定期更新 近期部分重要进展： 1、赵继宗院士牵头制定的《植入式脑机接口临床应用路径管理中国专家共识（2026 版）》 ...

证券之星消息，截至2026年2月3日收盘，美好医疗(301363)报收于31.94元，上涨4.01%，换手率 2.58%，成交量9.62万手，成交额3.06亿元。 2月3日的资金流向数据方面，主力资金净流入1553.92万元，占总成交额5.09%，游资资金净流出927.91 万元，占总成交额3.04%，散户资金净流出626.0万元，占总成交额2.05%。 美好医疗2025年三季报显示，前三季度公司主营收入11.94亿元，同比上升3.28%；归母净利润2.08亿 元，同比下降19.25%；扣非净利润2.03亿元，同比下降17.85%；其中2025年第三季度，公司单季度主营 收入4.62亿元，同比上升2.56%；单季度归母净利润9390.02万元，同比上升5.89%；单季度扣非净利润 9270.68万元，同比上升9.56%；负债率11.43%，投资收益490.31万元，财务费用-2739.1万元，毛利率 39.34%。美好医疗（301363）主营业务：医疗器械精密组件及产品的设计开发、制造和销售,为全球医 疗器械企业提供从产品研发到批量交付的全流程一站式服务。 该股最近90天内共有7家机构给出评级，买入评级7家； ...

证券日报网讯2月3日，美好医疗（301363）在互动平台回答投资者提问时表示，截至2026年1月30日， 公司股东总户数为29769户。 ...

Core Viewpoint - The ChiNext Medical Index (970082) closed at 3876.07 points on February 3, with a gain of 2.37% and a trading volume of 13.236 billion yuan, indicating positive market sentiment in the medical sector [1]. Group 1: Index Performance - The ChiNext Medical Index saw 49 constituent stocks rise, with NuoSiGe leading the gains at 8.76% [1]. - The index's turnover rate was 1.71%, reflecting moderate trading activity [1]. Group 2: Top Constituents - The top ten constituents of the ChiNext Medical Index include: - YuanEr Eye Hospital (sz300015) with a weight of 9.18% and a latest price of 11.04 yuan, up 1.28% [1]. - MaiRui Medical (sz300760) with a weight of 8.95% and a latest price of 188.15 yuan, up 0.56% [1]. - TaiGe Medical (sz300347) with a weight of 8.52% and a latest price of 63.20 yuan, up 4.97% [1]. - KangLong HuaCheng (sz300759) with a weight of 7.18% and a latest price of 29.61 yuan, up 2.10% [1]. - LePu Medical (sz300003) with a weight of 4.96% and a latest price of 17.83 yuan, up 1.89% [1]. - New Industry (sz300832) with a weight of 4.73% and a latest price of 54.50 yuan, up 2.60% [1]. - AiMeiKe (sz300896) with a weight of 4.49% and a latest price of 147.57 yuan, up 4.56% [1]. - YingKe Medical (sz300677) with a weight of 4.14% and a latest price of 40.55 yuan, up 1.38% [1]. - FuRui Medical (sz300049) with a weight of 3.55% and a latest price of 67.33 yuan, up 1.45% [1]. - HuaDa Gene (sz300676) with a weight of 3.15% and a latest price of 50.30 yuan, up 2.57% [1]. Group 3: Capital Flow - The net inflow of main funds into the ChiNext Medical Index constituents totaled 145 million yuan, while retail investors experienced a net outflow of 106 million yuan [1]. - The detailed capital flow indicates that TaiGe Medical had a main fund net inflow of 10.514 million yuan, while retail investors had a net outflow of 18.28% [2].

Core Viewpoint - The medical device sector experienced a rise of 1.42% on February 3, with Huakang Clean leading the gains, while the overall market indices also showed positive performance [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4067.74, up by 1.29% [1]. - The Shenzhen Component Index closed at 14127.1, up by 2.19% [1]. Group 2: Top Gainers in Medical Device Sector - Huakang Clean (301235) closed at 53.83, with a gain of 9.86% and a trading volume of 114,200 shares, amounting to a transaction value of 610 million yuan [1]. - Baocait (300246) closed at 13.15, up by 7.96% with a trading volume of 178,500 shares, totaling 229 million yuan [1]. - Yirui Technology (688301) closed at 119.24, increasing by 7.10% with a trading volume of 41,000 shares, resulting in a transaction value of 477 million yuan [1]. - Hualan Co. (301093) closed at 86.08, up by 6.45% with a trading volume of 60,900 shares, totaling 482 million yuan [1]. - Tianzhihang (688277) closed at 24.18, increasing by 6.10% with a trading volume of 159,300 shares, amounting to 379 million yuan [1]. Group 3: Market Outflows and Inflows - The medical device sector saw a net outflow of 253 million yuan from institutional investors and a net outflow of 112 million yuan from speculative funds, while retail investors had a net inflow of 365 million yuan [2]. - The detailed fund flow for individual stocks indicates varying levels of net inflow and outflow among different companies [3].

脑机接口月谈——产业及公司篇 20260202 摘要 国家及地方政策积极推动脑机接口发展，七部委发布指导意见，多地医 保探索支持，目标是到 2030 年培育 2-3 家全球领军企业和一批专精特 新企业，解决支付端问题，推动商业模式从产品销售向服务转化。 高校和科研院所在脑机接口技术研发中扮演关键角色，清华大学、中科 院、浙江大学等团队在侵入式、非侵入式和介入式脑机接口研究上取得 进展，其临床试验方案对市场具有重要指导意义。 脑机接口产业链关键组件包括电极（价值量最高）、芯片和手术机器人， 微纳加工工艺复杂，技术壁垒高。Neuralink、阶梯医疗和脑虎科技等 公司在手术机器人领域有所布局。 多重因素驱动脑机接口产业发展，包括政策支持、技术研发和临床试验 推进、企业积极布局核心组件及配套设备，预计到 2030 年中国将涌现 一批全球领军企业。 脑接口技术上游环节涉及材料、算法、电极和微纳加工等，汉威科技、 科大讯飞、东威半岛等公司在柔性传感器、算法等领域有布局，值得重 点关注。 Q&A 脑机接口产业目前的发展状况如何？有哪些值得关注的政策和市场动态？ 脑机接口产业目前处于初期发展阶段，但未来空间巨大。自 202 ...